

Oppdatering på EUnetHTA og lovforslag

Møte i Bestillerforum RHF
8. januar 2021

Sari Ormstad, Folkehelseinstituttet

1. EUnetHTA Joint Action 3: aktiviteter i det siste året
2. Informasjon om lovforslag mottatt via EUnetHTA
3. Hva skjer etter EUnetHTA Joint Action 3?

Focus of the prolongation (June 2020- May 2021)

Work package 4 (Joint Production) related:


1. Prioritising Covid-19-related work
 - 22 Rolling Collaborative Reviews*
 - 4 Rapid Collaborative Reviews*
2. The completion of ongoing Relative Effectiveness Assessments
 - 13 completed and 3 ongoing assessments on pharmaceutical technologies*
 - 25 completed and 3 ongoing assessments on other technologies*
3. The finalisation of assessment procedures and methodologies
4. The finalisation of the Future Model of Cooperation on HTA White Paper
 - Public consultation of the White Paper around March 2021

EC Proposal – state of play

- Negotiations of the proposal resumed under the German Presidency
- CWP meeting – 1st of September
- Timeline by German Presidency (presented during HTA Network meeting 27/10)
 - **November 2020**
compromise proposal of DEU Presidency
 - **November /December 2020**
Council Working Party Pharma discusses the compromise
 - **2 December 2020**
HTA progress report at EPSCO Health Ministers Council
 - **follow-up procedure I/2021 to be defined by Portuguese Presidency**

Governance


EUnetHTA – project-based governance



PT = pharmaceuticals; OT = other technologies

Governance


EU framework for cooperation



MP = medicinal products; MD = medical devices

Source: European Commission

“Bridging period” before implementation



Møte med HOD, SLV, FHI og EUnetHTA

9. desember 2020